迈瑞展区内人头攒动，启元大模型、瑞影、瑞检等系列产品正进行现场演示，工作人员讲解产品特性， 吸引了众多观众咨询交流；西门子医疗展区内，几台磁共振成像设备静静陈列，专业讲解员围绕设备的 临床应用场景、影像清晰度提升等核心优势展开介绍，让观众近距离感受高端医疗装备的科技魅力。 一批AI药械、手术机器人领域的产品引人关注。精锋医疗展示了其自主研发的多孔腔镜手术机器人、 单孔腔镜手术机器人、支气管镜手术机器人等丰富完整的产品组合，并为观众演示精细的手术画面。粒 影科技发布的AI+药械研发公共服务平台，深度融合"AI蛋白质结构预测与设计""AI底盘细胞改造"等多 项自研核心技术，可将传统需数年的研发周期缩短至数月。 药械产值1576亿元 12月18日，2025深圳国际高性能医疗器械展暨创新医药展在深圳会展中心举行。此次展会设置了医学影 像及放疗、医学检验、应急救治及康复、人工智能及机器人、创新医药、供应链等"8+1+1"十大展区， 吸引了300余家全球医药与医疗器械领域的领军企业和机构参展，展示千余件创新产品，涵盖高端医疗 器械、创新药、生物制造、AI+药械、消费医疗、核心零部件等深圳乃至国内药械领域的最新成果，为 医 ...

Core Viewpoint - Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (Mindray) announced plans to issue H-shares and list on the Hong Kong Stock Exchange to support its internationalization strategy and enhance capital strength [1] Group 1: Internationalization Strategy - The funds raised will be used to advance Mindray's international strategy, global business layout, increase R&D investment, and supplement operational funds, aligning with its three strategic directions: digitalization, streamlining, and internationalization [1] - Mindray is the only domestic medical device company in the global top 30, with a net asset of 39 billion yuan as of mid-2023 and a total dividend payout of 3.3 billion yuan this year, maintaining a dividend ratio of 65.1% [1][2] Group 2: Business Operations and Market Position - Mindray has established three main business segments: in vitro diagnostics, life information and support, and medical imaging, with a comprehensive product line in the industry [2] - The company has expanded its global presence with production bases in 14 countries, 12 R&D centers, and 64 overseas subsidiaries, employing over 3,000 local staff [2] - Mindray's overseas revenue has consistently grown for seven years, with international business accounting for 50% of total revenue in the first half of this year, indicating a deepening global strategy [2] Group 3: R&D and Innovation - R&D is considered the "lifeline" of Mindray, with R&D investment reaching 1.777 billion yuan in the first half of 2025, representing 10.61% of revenue, and a total of 20.646 billion yuan since its A-share listing in 2018 [3] - Mindray has integrated "equipment + IT + AI" and completed a digital medical ecosystem by 2025, enhancing its product offerings and transitioning to comprehensive digital solutions [3] - The successful listing in Hong Kong is expected to provide momentum for strategic collaboration, broaden financing channels, and enhance international brand recognition [3]

Core Viewpoint - Mindray Medical has announced its second interim profit distribution plan for 2025, continuing its commitment to shareholder returns through cash dividends, reflecting the company's confidence in future growth and alignment with national policies encouraging cash dividends [1][2][3] Dividend Distribution - The company will distribute a cash dividend of RMB 13.10 per 10 shares, totaling RMB 17.10 billion for the first interim distribution and an expected cumulative cash dividend of RMB 32.98 billion for 2025 [1][2] - Since its listing in 2018, Mindray has maintained a consistent dividend policy, with total dividends reaching RMB 357 billion over seven years [1][2] Shareholder Return Strategy - Mindray has outlined a three-year shareholder return plan (2025-2027), committing to at least one profit distribution annually, primarily in cash, contingent on profit distribution conditions [2] - The company has increased its cash dividend ratio, achieving 60.72% in 2023 and 65.15% in 2024, indicating a strong focus on returning value to shareholders [2] Business Growth and Innovation - Mindray's international business revenue reached RMB 83.32 billion in the first half of 2025, a year-on-year increase of 5.39%, now accounting for 50% of total revenue [4] - The company has made significant advancements in technology and innovation, establishing a comprehensive digital healthcare ecosystem that integrates AI and medical devices, enhancing its competitive edge [3][4] Market Position and Future Outlook - Mindray's global market ranking has improved from 36th in 2020 to 23rd in 2023, reflecting its growing presence in the medical device sector and its ambition to enter the top 10 globally [4] - The company anticipates continued growth in international business, particularly in developing countries, supported by localized platform development and high-end client acquisition [4]